Sharon Tetlow

Sharon Tetlow is a serial CFO. As the managing partner of Potrero Hills Advisors, Sharon works with CEOs of emerging biotechs to execute their finance strategies as an interim CFO, including fundraising, overseeing private and public company compliance and building finance teams. Her clients and recent IPO experiences include 4D Molecular Therapeutics, Allakos, CytomX and Ocera Therapeutics. Sharon also serves on the Board of Armetheon, Inc. 

Sharon Tetlow has over a dozen years of experience as chief financial officer in life sciences, and a strong track record of strategic execution and raising capital. She was most recently senior vice president and CFO of Cell Genesys, a publicly traded biotechnology company in which she was instrumental in selling to BioSante (BPAX). She served as a venture partner at Apax Partners, a private equity and venture firm, and previously served as senior vice president and chief financial officer of diaDexus, where she raised private capital to fund the development and successful launch of the company’s first product.

She also served as CFO of Reprogen and Terrapin, both private biotechnology companies. Prior to Terrapin, Ms. Tetlow worked in finance at Synergen, Genentech and Eli Lilly. Ms Tetlow began her career in Washington D.C. where she worked in consulting at Lewin and Associates and then at the Brookings Institution. She holds a BA from the University of Delaware and an MBA from Stanford University.